|
1
|
Perou CM, Sorlie T, Eisen MB, et al:
Molecular portraits of human breast tumours. Nature. 406:747–752.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertucci F, Finetti P, Cervera N, et al:
How basal are triple-negative breast cancers? Int J Cancer.
123:236–240. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sorlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sorlie T, Tibshirani R, Parker J, et al:
Repeated observation of breast tumor subtypes in independent gene
expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sotiriou C, Neo SY, McShane LM, et al:
Breast cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
van ‘t Veer LJ, Dai H, van de Vijver MJ,
et al: Gene expression profiling predicts clinical outcome of
breast cancer. Nature. 415:530–536. 2002.PubMed/NCBI
|
|
7
|
Carey LA, Perou CM, Livasy CA, et al:
Race, breast cancer subtypes and survival in the Carolina Breast
Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lund MJ, Trivers KF, Porter PL, et al:
Race and triple negative threats to breast cancer survival: a
population-based study in Atlanta, GA. Breast Cancer Res Treat.
113:357–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carey LA, Dees EC, Sawyer L, et al: The
triple negative paradox: primary tumor chemosensitivity of breast
cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liedtke C, Mazouni C, Hess KR, et al:
Response to neoadjuvant therapy and long-term survival in patients
with triple-negative breast cancer. J Clin Oncol. 26:1275–1281.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Rakha EA, El-Sayed ME, Green AR, Lee AH,
Robertson JF and Ellis IO: Prognostic markers in triple-negative
breast cancer. Cancer. 109:25–32. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rouzier R, Perou CM, Symmans WF, et al:
Breast cancer molecular subtypes respond differently to
preoperative chemotherapy. Clin Cancer Res. 11:5678–5685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dent R, Trudeau M, Pritchard KI, et al:
Triple-negative breast cancer: clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haffty BG, Yang Q, Reiss M, et al:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar
|
|
15
|
Singh-Ranger G, Salhab M and Mokbel K: The
role of cyclooxygenase-2 in breast cancer: review. Breast Cancer
Res Treat. 109:189–198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Basu GD, Liang WS, Stephan DA, et al: A
novel role for cyclooxygenase-2 in regulating vascular channel
formation by human breast cancer cells. Breast Cancer Res.
8:R692006. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Basu GD, Pathangey LB, Tinder TL, Lagioia
M, Gendler SJ and Mukherjee P: Cyclooxygenase-2 inhibitor induces
apoptosis in breast cancer cells in an in vivo model of spontaneous
metastatic breast cancer. Mol Cancer Res. 2:632–642.
2004.PubMed/NCBI
|
|
18
|
Hoellen F, Kelling K, Dittmer C, Diedrich
K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast
cancer. Anticancer Res. 31:4359–4367. 2011.PubMed/NCBI
|
|
19
|
Jendrossek V: Targeting apoptosis pathways
by celecoxib in cancer. Cancer Lett. 332:313–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu B, Qu L and Tao H: Cyclo-oxygenase 2
up-regulates the effect of multidrug resistance. Cell Biol Int.
34:21–25. 2009.PubMed/NCBI
|
|
21
|
Sahin M, Sahin E and Gumuslu S:
Cyclooxygenase-2 in cancer and angiogenesis. Angiology. 60:242–253.
2009.PubMed/NCBI
|
|
22
|
Singh B, Berry JA, Shoher A, Ramakrishnan
V and Lucci A: COX-2 overexpression increases motility and invasion
of breast cancer cells. Int J Oncol. 26:1393–1399. 2005.PubMed/NCBI
|
|
23
|
Thill M, Fischer D, Becker S, et al:
Prostaglandin metabolizing enzymes in correlation with vitamin D
receptor in benign and malignant breast cell lines. Anticancer Res.
29:3619–3625. 2009.
|
|
24
|
Denkert C, Winzer KJ, Muller BM, et al:
Elevated expression of cyclooxygenase-2 is a negative prognostic
factor for disease free survival and overall survival in patients
with breast carcinoma. Cancer. 97:2978–2987. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haffty BG, Yang Q, Moran MS, Tan AR and
Reiss M: Estrogen-dependent prognostic significance of
cyclooxygenase-2 expression in early-stage invasive breast cancers
treated with breast-conserving surgery and radiation. Int J Radiat
Oncol Biol Phys. 71:1006–1013. 2008. View Article : Google Scholar
|
|
26
|
Kim HS, Moon HG, Han W, et al: COX2
overexpression is a prognostic marker for stage III breast cancer.
Breast Cancer Res Treat. 132:51–59. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ristimaki A, Sivula A, Lundin J, et al:
Prognostic significance of elevated cyclooxygenase-2 expression in
breast cancer. Cancer Res. 62:632–635. 2002.PubMed/NCBI
|
|
28
|
Schmitz KJ, Callies R, Wohlschlaeger J, et
al: Overexpression of cyclo-oxygenase-2 is an independent predictor
of unfavourable outcome in node-negative breast cancer, but is not
associated with protein kinase B (Akt) and mitogen-activated
protein kinase (ERK1/2, p38) activation or with Her-2/neu
signalling pathways. J Clin Pathol. 59:685–691. 2006.
|
|
29
|
Spizzo G, Gastl G, Wolf D, et al:
Correlation of COX-2 and Ep-CAM overexpression in human invasive
breast cancer and its impact on survival. Br J Cancer. 88:574–578.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
van Nes JG, de Kruijf EM, Faratian D, et
al: COX2 expression in prognosis and in prediction to endocrine
therapy in early breast cancer patients. Breast Cancer Res Treat.
125:671–685. 2011.PubMed/NCBI
|
|
31
|
Kargi A, Uysal M, Bozcuk H, Coskun HS,
Savas B and Ozdogan M: The importance of COX-2 expression as
prognostic factor in early breast cancer. J BUON. 18:579–584.
2013.PubMed/NCBI
|
|
32
|
Lucci A, Krishnamurthy S, Singh B, et al:
Cyclooxygenase-2 expression in primary breast cancers predicts
dissemination of cancer cells to the bone marrow. Breast Cancer Res
Treat. 117:61–68. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wulfing P, Diallo R, Muller C, et al:
Analysis of cyclooxygenase-2 expression in human breast cancer:
high throughput tissue microarray analysis. J Cancer Res Clin
Oncol. 129:375–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhou L, Li K, Luo Y, et al: Novel
prognostic markers for patients with triple-negative breast cancer.
Hum Pathol. 44:2180–2187. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Witton CJ, Hawe SJ, Cooke TG and Bartlett
JM: Cyclooxygenase 2 (COX2) expression is associated with poor
outcome in ER-negative, but not ER-positive, breast cancer.
Histopathology. 45:47–54. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition.
Springer; New York, NY: 421. 2010
|
|
37
|
Black MM and Speer FD: Nuclear structure
in cancer tissues. Surg Gynecol Obstet. 105:97–102. 1957.PubMed/NCBI
|
|
38
|
Mazouni C, Peintinger F, Wan-Kau S, et al:
Residual ductal carcinoma in situ in patients with complete
eradication of invasive breast cancer after neoadjuvant
chemotherapy does not adversely affect patient outcome. J Clin
Oncol. 25:2650–2655. 2007. View Article : Google Scholar
|
|
39
|
O’Connor JK, Avent J, Lee RJ, Fischbach J
and Gaffney DK: Cyclooxygenase-2 expression correlates with
diminished survival in invasive breast cancer treated with
mastectomy and radiotherapy. Int J Radiat Oncol Biol Phys.
58:1034–1040. 2004.PubMed/NCBI
|
|
40
|
Zerkowski MP, Camp RL, Burtness BA, Rimm
DL and Chung GG: Quantitative analysis of breast cancer tissue
microarrays shows high cox-2 expression is associated with poor
outcome. Cancer Invest. 25:19–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: a population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar
|
|
42
|
Bhargava R, Beriwal S, Dabbs DJ, et al:
Immunohistochemical surrogate markers of breast cancer molecular
classes predicts response to neoadjuvant chemotherapy: a single
institutional experience with 359 cases. Cancer. 116:1431–1439.
2010. View Article : Google Scholar
|
|
43
|
Morris GJ, Naidu S, Topham AK, et al:
Differences in breast carcinoma characteristics in newly diagnosed
African-American and Caucasian patients: a single-institution
compilation compared with the National Cancer Institute’s
Surveillance, Epidemiology and End Results database. Cancer.
110:876–884. 2007.
|
|
44
|
Tischkowitz M, Brunet JS, Begin LR, et al:
Use of immunohistochemical markers can refine prognosis in triple
negative breast cancer. BMC Cancer. 7:1342007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Davis TW, Hunter N, Trifan OC, Milas L and
Masferrer JL: COX-2 inhibitors as radiosensitizing agents for
cancer therapy. Am J Clin Oncol. 26:S58–S61. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Raju U, Ariga H, Dittmann K, Nakata E, Ang
KK and Milas L: Inhibition of DNA repair as a mechanism of enhanced
radioresponse of head and neck carcinoma cells by a selective
cyclooxygenase-2 inhibitor, celecoxib. Int J Radiat Oncol Biol
Phys. 63:520–528. 2005. View Article : Google Scholar
|
|
47
|
Lau L, Hansford LM, Cheng LS, et al:
Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance
chemotherapy-induced apoptosis in neuroblastoma. Oncogene.
26:1920–1931. 2007. View Article : Google Scholar : PubMed/NCBI
|
